InvestorsHub Logo
Followers 1521
Posts 89052
Boards Moderated 5
Alias Born 05/09/2004

Re: ~MulaGreen~ post# 7889

Saturday, 06/26/2021 12:13:16 AM

Saturday, June 26, 2021 12:13:16 AM

Post# of 13742
"This batch specifically ran for submission to the Ministry of Health in the DR. This is the next step in achieving approval from the regulatory body to continue clinical trials on Escozine® as a treatment for the SARS-CoV-2 (COVID-19) virus. Once the batch is reviewed and the Medical Bioethics committee issues approval of the study’s construct, Medolife plans to conduct a Phase III double-blind placebo clinical trial, seeking regulatory approval of the drug. Beyond its COVID-19 clinical program on Escozine®, the product was also recently awarded product re-registration as an alternative medicine for the treatment of cancer."

https://finance.yahoo.com/news/medolife-rx-successfully-produces-medical-123000497.html

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.